TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma
26 oct. 2022 07h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported...
TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology
13 oct. 2022 07h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced...
TransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines Conference
27 sept. 2022 08h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced...
TransCode Therapeutics Appoints MicroRNA Pioneer, Dr. Frank Slack, to its Advisory Board
08 sept. 2022 08h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced...
TransCode Therapeutics Reports Second Quarter 2022 Results; Provides Business Update
15 août 2022 16h15 HE
|
TransCode Therapeutics, Inc.
BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported...
TransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for Oncology
02 août 2022 07h00 HE
|
TransCode Therapeutics, Inc.
BOSTON and HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA oncology company, and The University of Texas MD Anderson...
TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio
11 juil. 2022 16h05 HE
|
TransCode Therapeutics, Inc.
BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced extension of its...
TransCode Therapeutics to Participate at BIO International Convention
09 juin 2022 09h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, June 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the BIO International Convention to be held June...
TransCode Therapeutics Receives National Institutes of Health (NIH) Notice of Award
01 juin 2022 09h00 HE
|
TransCode Therapeutics, Inc.
Funding is part of a 2021 Fast-Track Small Business Innovation Research (SBIR) grant to Support Clinical Development of First-in-Class Therapy for Advanced Solid Tumors First SBIR program...
TransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference
20 mai 2022 09h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the H.C. Wainwright Global Investment Conference. The in-person...